Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Lower Survival for Obese Kidney-Transplant Patients

By HospiMedica staff writers
Posted on 14 Dec 2006
Obese kidney-transplant patients are twice as likely to die or suffer organ failure during the first year following surgery, according to a new study.

Nephrology specialists from seven university hospitals across the Netherlands studied the medical profiles of 4,245 adults who had received kidney transplants, using data from the Netherlands organ transplantation registry. More...
In 2,067 cases, there was sufficient information to calculate the body mass index (BMI)--based on weight and height--at the time of the kidney transplant. Obese patients in the study group tended to be older and were more likely to be female.

The researchers found that 6% of patients with a BMI of more than 30 died in the first year after transplant, compared with 3% of patients with a BMI of less than 30. By year five, the difference was even greater, with an 81 % survival rate for the obese patients and an 89 % survival rate for patients who were not obese. The same pattern emerged when the researchers looked at the success of the transplant itself. A year after the transplant was carried out, 14% of obese patients had experienced a transplant failure, compared with 8% of non-obese patients. After five years, 71% of obese patients still had a successfully transplanted kidney, compared with 80% of the patients with a lower BMI.

Obese patients were more likely to suffer transplant failure through infection or permanent non-functioning, but the numbers for obese and non-obese patients were both fairly low. There were no significant differences between the two groups when it came to why patients died, but there was a trend for obese patients to suffer more infections and fatal heart conditions. The study was published in the November 2006 issue of Transplant International.

"Our conclusion is that it's not fair to deny obese patients the chance of a kidney transplant as they still do better after a transplant than on dialysis,” said lead author Dr. Jeroen Aalten from the department of nephrology at the University Medical Center Nijmegen (The Netherlands). "However we shouldn't disregard the increased risk for obese patients after transplantation and we also need to bear in mind that it is important to give scarce resources to patients with the lowest risk.”



Related Links:
University Medical Center Nijmegen

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.